|
NR 10-12/2008
|
|
|
|
|
|
|
|
|
Terapia anty-VEGF w
leczeniu neowaskularyzacji plamkowej towarzyszącej
krótkowzroczności – opis przypadków
Anty-VEGF therapy in the
treatment of myopic macular choroidal neovascularization – cases
report
Małgorzata Figurska, Andrzej Stankiewicz
Z Kliniki Okulistyki Wojskowego Instytutu Medycznego w Warszawie
Kierownik: prof. dr hab. n. med. Andrzej Stankiewicz |
|
|
| Summary: |
Purpose: Myopia is
the second most frequent cause of CNV after AMD. Since
the introduction of verteporfin photodynamic therapy and
anti-angiogenic drugs into clinical practice, major
changes occurred in the treatment of subfoveal exudative
maculopathy associated with myopia.The aim of the paper
is to present the effect of intravitreal injections
ranibizumab (Lucentis) for myopic choroidal
neovascularization .
Material and methods: The study included two
patients (25 and 55 years old women) with high myopia.
Diagnosis and monitoring of the treatment were based on
fluorescein angiography and optical coherence tomography.
Results: In 55-years old woman after two
injections central retinal leakage decreased in
fluorescein angiography and optical coherence tomography
and visual acuity improved of two lines(10letters).
After 9months follow-up in 25 years old woman`s after
three injections of Lucentis, visual acuity improved of
three lines on ETDRS chart (15 letters). The leakage in
fluorescein angiography was closed.
Conclusions: Intravitreal injections therapy of
ranibizumab may be a therapeutic option for CNV
associated with myopia. It causes chance for decreased
central retinal thickness and increased visual acuity,
particularly in view of the young patients. One must
take note of the other illness associated with CNV in
myopic eyes like as epiretinal membranes or
vitreoretinal tractions . |
| Słowa kluczowe: |
krótkowzroczność,
neowaskularyzacja odnaczyniówkowa, iniekcje
doszklistkowe, ranibizumab. |
| Key words: |
myopia, choroidal
neovascularization, intravitreal injections, ranibizumab. |
|
|
|
|
|
|
